DesignMedix, Inc. was founded in 2008 to develop drugs to overcome drug resistance. The company's initial focus is on oral drugs to treat malaria, which kills over 600,000 people per year and affects up to 500 million people. The company has developed a series of novel, safe and effective drugs that have the potential for low-cost production.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 07/19/14 | $1,500,000 | Seed |
Bellingham Angel Investors Keiretsu Forum Oregon Angel Fund Portland Seed Fund Seraph Angel Network Willamette Angel Conference | undisclosed |
